Back

XtalPi begins IND-enabling studies for hair-loss drug candidate

Verifying
  • XtalPi advanced its proprietary hair-loss drug program into IND-enabling studies.
  • One candidate matched 5% topical minoxidil in mice at one-hundredth its concentration.
  • XtalPi is evaluating pharmacology, safety and CMC studies for a future IND application.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.